 Martin Krsak
Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonia, Viral | 5 | 2020 | 338 | 2.070 |
Why?
| | Coronavirus Infections | 5 | 2020 | 330 | 2.060 |
Why?
| | Antibodies, Viral | 3 | 2021 | 520 | 1.720 |
Why?
| | Prisons | 5 | 2020 | 72 | 1.680 |
Why?
| | Teicoplanin | 3 | 2021 | 17 | 1.520 |
Why?
| | Betacoronavirus | 5 | 2020 | 250 | 1.440 |
Why?
| | Pandemics | 5 | 2020 | 1320 | 1.310 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2020 | 61 | 1.280 |
Why?
| | Prisoners | 2 | 2020 | 124 | 1.160 |
Why?
| | HIV Infections | 4 | 2023 | 2469 | 1.050 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 413 | 0.960 |
Why?
| | Anti-Bacterial Agents | 5 | 2024 | 1482 | 0.930 |
Why?
| | Immunity, Humoral | 2 | 2021 | 112 | 0.880 |
Why?
| | Vaccination | 2 | 2021 | 1204 | 0.860 |
Why?
| | Telemedicine | 2 | 2020 | 662 | 0.770 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 28 | 0.690 |
Why?
| | Buprenorphine | 1 | 2023 | 134 | 0.680 |
Why?
| | Pressure Ulcer | 1 | 2020 | 31 | 0.660 |
Why?
| | Medical Errors | 1 | 2020 | 85 | 0.650 |
Why?
| | Liver Diseases, Parasitic | 1 | 2019 | 3 | 0.650 |
Why?
| | Fascioliasis | 1 | 2019 | 6 | 0.640 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 222 | 0.630 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 139 | 0.610 |
Why?
| | Cannabis | 2 | 2023 | 384 | 0.610 |
Why?
| | Osteomyelitis | 1 | 2020 | 105 | 0.600 |
Why?
| | Dyspnea | 1 | 2019 | 211 | 0.570 |
Why?
| | Patient Safety | 1 | 2020 | 277 | 0.560 |
Why?
| | Outpatients | 1 | 2020 | 326 | 0.560 |
Why?
| | Eosinophilia | 1 | 2019 | 186 | 0.550 |
Why?
| | RNA, Viral | 1 | 2020 | 565 | 0.550 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 668 | 0.520 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2015 | 256 | 0.430 |
Why?
| | Humans | 24 | 2024 | 114711 | 0.370 |
Why?
| | Myocardial Infarction | 1 | 2015 | 927 | 0.300 |
Why?
| | Colorado | 3 | 2023 | 4100 | 0.280 |
Why?
| | Stroke | 1 | 2015 | 1022 | 0.270 |
Why?
| | Prevalence | 2 | 2023 | 2251 | 0.260 |
Why?
| | United States | 5 | 2020 | 12184 | 0.240 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 771 | 0.240 |
Why?
| | Endocarditis, Bacterial | 1 | 2024 | 36 | 0.220 |
Why?
| | Endocarditis | 1 | 2024 | 32 | 0.220 |
Why?
| | Ohio | 1 | 2023 | 135 | 0.220 |
Why?
| | Prospective Studies | 3 | 2021 | 6220 | 0.220 |
Why?
| | Arthritis, Infectious | 1 | 2024 | 49 | 0.210 |
Why?
| | Prosthesis-Related Infections | 1 | 2024 | 70 | 0.210 |
Why?
| | Vancomycin | 1 | 2024 | 75 | 0.210 |
Why?
| | Policy | 1 | 2023 | 137 | 0.190 |
Why?
| | Goals | 1 | 2023 | 147 | 0.190 |
Why?
| | Renal Insufficiency | 1 | 2023 | 137 | 0.190 |
Why?
| | Young Adult | 3 | 2023 | 10472 | 0.190 |
Why?
| | Invasive Fungal Infections | 1 | 2021 | 10 | 0.190 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 238 | 0.190 |
Why?
| | Aspergillosis | 1 | 2021 | 23 | 0.180 |
Why?
| | Candidiasis | 1 | 2021 | 51 | 0.180 |
Why?
| | Vaccines, Synthetic | 1 | 2021 | 124 | 0.180 |
Why?
| | Marijuana Use | 1 | 2023 | 167 | 0.180 |
Why?
| | Immunity | 1 | 2021 | 121 | 0.180 |
Why?
| | History, 17th Century | 1 | 2020 | 15 | 0.180 |
Why?
| | Immunologic Surveillance | 1 | 2020 | 19 | 0.180 |
Why?
| | Burns | 1 | 2023 | 237 | 0.170 |
Why?
| | Quarantine | 1 | 2020 | 24 | 0.170 |
Why?
| | Drug Users | 1 | 2020 | 41 | 0.170 |
Why?
| | Cortical Bone | 1 | 2020 | 18 | 0.170 |
Why?
| | Immunoassay | 1 | 2020 | 95 | 0.170 |
Why?
| | Homosexuality, Male | 1 | 2021 | 170 | 0.170 |
Why?
| | Policy Making | 1 | 2020 | 81 | 0.170 |
Why?
| | Communicable Disease Control | 1 | 2020 | 67 | 0.170 |
Why?
| | History, 21st Century | 1 | 2020 | 159 | 0.170 |
Why?
| | Delayed-Action Preparations | 1 | 2020 | 159 | 0.160 |
Why?
| | History, 20th Century | 1 | 2020 | 264 | 0.160 |
Why?
| | Vulnerable Populations | 1 | 2020 | 134 | 0.160 |
Why?
| | Off-Label Use | 1 | 2019 | 51 | 0.160 |
Why?
| | Skilled Nursing Facilities | 1 | 2020 | 121 | 0.160 |
Why?
| | Afghanistan | 1 | 2019 | 108 | 0.150 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 486 | 0.150 |
Why?
| | Mortality | 1 | 2020 | 287 | 0.150 |
Why?
| | Health Status Disparities | 1 | 2020 | 200 | 0.150 |
Why?
| | Global Health | 1 | 2020 | 287 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 923 | 0.150 |
Why?
| | Retrospective Studies | 5 | 2024 | 12558 | 0.140 |
Why?
| | Risk-Taking | 1 | 2020 | 333 | 0.140 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 295 | 0.140 |
Why?
| | Acute Kidney Injury | 1 | 2024 | 638 | 0.140 |
Why?
| | Self Report | 1 | 2021 | 696 | 0.140 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1079 | 0.130 |
Why?
| | Treatment Outcome | 3 | 2024 | 9089 | 0.130 |
Why?
| | Adult | 4 | 2024 | 30562 | 0.130 |
Why?
| | Male | 5 | 2024 | 55669 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2020 | 645 | 0.120 |
Why?
| | Pilot Projects | 1 | 2019 | 1373 | 0.120 |
Why?
| | Length of Stay | 1 | 2019 | 962 | 0.120 |
Why?
| | Hospitals | 1 | 2019 | 581 | 0.120 |
Why?
| | Female | 5 | 2024 | 59573 | 0.120 |
Why?
| | Risk Assessment | 1 | 2023 | 2968 | 0.120 |
Why?
| | Chronic Disease | 1 | 2020 | 1579 | 0.120 |
Why?
| | CD4 Lymphocyte Count | 1 | 2015 | 257 | 0.120 |
Why?
| | Health Services Accessibility | 1 | 2020 | 763 | 0.120 |
Why?
| | Middle Aged | 3 | 2024 | 26740 | 0.110 |
Why?
| | Mass Screening | 1 | 2020 | 1006 | 0.110 |
Why?
| | Cause of Death | 1 | 2015 | 361 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2019 | 833 | 0.100 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 4624 | 0.100 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1075 | 0.100 |
Why?
| | Cohort Studies | 1 | 2021 | 4895 | 0.090 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 373 | 0.090 |
Why?
| | Biomarkers | 1 | 2021 | 3408 | 0.090 |
Why?
| | Inflammation | 1 | 2021 | 2480 | 0.090 |
Why?
| | Time Factors | 1 | 2020 | 6114 | 0.090 |
Why?
| | Incidence | 1 | 2015 | 2314 | 0.080 |
Why?
| | Aged, 80 and over | 1 | 2019 | 6346 | 0.080 |
Why?
| | Aged | 3 | 2024 | 19075 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2015 | 4411 | 0.070 |
Why?
| | Debridement | 1 | 2024 | 73 | 0.050 |
Why?
| | Treatment Failure | 1 | 2024 | 330 | 0.050 |
Why?
| | Creatinine | 1 | 2023 | 425 | 0.050 |
Why?
| | Risk Factors | 1 | 2015 | 8634 | 0.050 |
Why?
| | Adolescent | 1 | 2019 | 17856 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2021 | 300 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 604 | 0.040 |
Why?
| | Antifungal Agents | 1 | 2021 | 128 | 0.040 |
Why?
| | Crowding | 1 | 2020 | 37 | 0.040 |
Why?
| | Frail Elderly | 1 | 2020 | 106 | 0.040 |
Why?
| | Nursing Homes | 1 | 2020 | 138 | 0.040 |
Why?
| | Residence Characteristics | 1 | 2020 | 275 | 0.040 |
Why?
| | Urban Population | 1 | 2020 | 397 | 0.040 |
Why?
| | Occupational Exposure | 1 | 2020 | 255 | 0.040 |
Why?
| | Kidney | 1 | 2023 | 1188 | 0.030 |
Why?
| | Rural Population | 1 | 2020 | 446 | 0.030 |
Why?
| | Public Health | 1 | 2020 | 434 | 0.030 |
Why?
| | Quality of Life | 1 | 2021 | 2353 | 0.020 |
Why?
|
|
Krsak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|